Advenchen Laboratories is a small pharmaceutical company focusing on
pharmaceutical research and development involving small molecule cancer
drug discovery programs. Our scientists are looking for small molecule
kinase inhibitors, especially protein tyrosine kinases (PTK) inhibitors, that
target the regulation of various PTK for cancer treatment. Our proprietary
drug development product pipeline has demonstrated strong anti-tumor
activities and therapeutic benefits in various target scopes. It is believed that
our novel small molecules will bring breakthrough and promising therapies
as well as a prosperous future for cancer patients.
Our crucial capability is to create innovative chemical fragments and
scaffolds that may contribute better solubility, pharmacodynamics,
pharmcokinetics and toxicology profiles to bring us the most promising
preclinical and clinical candidates.